The role of photodynamic therapy for hilar cholangiocarcinoma

Korean Journal of Internal Medicine

Volumn 25, Issue 4, 2010, Pages 345-352

  Cheon, Young Koog ^a  

^a Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Bile duct neoplasms; Cholangiocarcinoma; Photodynamic therapy; Photosensitizing agents

Indexed keywords

PHOTOFRIN II;

ADVANCED CANCER; BILE DUCT CARCINOMA; BILIARY TRACT DRAINAGE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CHOLANGITIS; CHOLESTASIS; ENDOSCOPIC SURGERY; HUMAN; INTERMETHOD COMPARISON; NONHUMAN; PHOTODYNAMIC THERAPY; REVIEW; STENT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR ABLATION;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; HUMANS; PHOTOCHEMOTHERAPY; TREATMENT OUTCOME;

EID: 78650968885     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2010.25.4.345     Document Type: Review

References (35)

1. Oleinick NL, Evans HH. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res 1998;150(5 Suppl):S146-S156.
2. Wang KK. Current status of photodynamic therapy of Barrett's esophagus. Gastrointest Endosc 1999;49(3 Pt 2):S20-S23.
3. Dougherty TJ. An update on photodynamic therapy applications. J Clin Laser Med Surg 2002;20:3-7.
4. Rea DJ, Munoz-Juarez M, Farnell MB, et al. Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch Surg 2004;139:514-523.
5. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507-517.
6. Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005;100:2426-2430.
7. Ortner ME, Caca K, Berr F, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003;125:1355-1363.
8. Kremer B, Henne-Bruns D, Vogel I, Grimm H, Soehendra N. Impact of staging on treatment of biliary carcinoma. Endoscopy 1993;25:92-99.
9. Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, Blumgart LH. Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 1998;228:385-394.
10. Luman W, Cull A, Palmer KR. Quality of life in patients stented for malignant biliary obstructions. Eur J Gastroenterol Hepatol 1997;9:481-484.
11. Smith AC, Dowsett JF, Russell RC, Hatfield AR, Cotton PB. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 1994;344:1655-1660.
12. Polydorou AA, Cairns SR, Dowsett JF, et al. Palliation of proximal malignant biliary obstruction by endoscopic endoprosthesis insertion. Gut 1991;32:685-689.
13. Ducreux M, Liguory C, Lefebvre JF, et al. Management of malignant hilar biliary obstruction by endoscopy. Results and prognostic factors. Dig Dis Sci 1992;37:778-783.
14. Chang WH, Kortan P, Haber GB. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc 1998;47:354-362.
15. Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992;340:1488-1492.
16. Bowling TE, Galbraith SM, Hatfield AR, Solano J, Spittle MF. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut 1996;39:852-855.
17. Molt P, Hopfan S, Watson RC, Botet JF, Brennan MF. Intraluminal radiation therapy in the management of malignant biliary obstruction. Cancer 1986;57:536-544.
18. Pahernik SA, Dellian M, Berr F, Tannapfel A, Wittekind C, Goetz AE. Distribution and pharmacokinetics of Photofrin in human bile duct cancer. J Photochem Photobiol B 1998;47:58-62.
19. Weishaupt KR, Gomer CJ, Dougherty TJ. Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. Cancer Res 1976;36(7 Pt 1):2326-2329.
20. Henderson BW, Donovan JM. Release of prostaglandin E2 from cells by photodynamic treatment in vitro. Cancer Res 1989;49(24 Pt 1):6896-6900.
21. Ortner MA, Liebetruth J, Schreiber S, et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 1998;114:536-542.
22. Rumalla A, Baron TH, Wang KK, Gores GJ, Stadheim LM, de Groen PC. Endoscopic application of photodynamic therapy for cholangiocarcinoma. Gastrointest Endosc 2001;53:500-504.
23. Shim CS, Cheon YK, Cha SW, et al. Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment. Endoscopy 2005;37:425-433.
24. Wong M, Wang KK, Alexander GL, et al. Cholorin E6 and hematophorphyrin derivative (HPD) on photodynamic therapy of a human cholangiocarcinoma model [abstract]. Gastroenterology 1996;110:595.
25. McCaughan JS Jr, Mertens BF, Cho C, Barabash RD, Payton HW. Photodynamic therapy to treat tumors of the extrahepatic biliary ducts. A case report. Arch Surg 1991;126:111-113.
26. Wong Kee Song LM, Wang KK, Zinsmeister AR. Mono-Laspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model. Cancer 1998;82:421-427.
27. Cheon YK, Kim YS, Cho YD, et al. Experimental interstitial photodynamic therapy of the Morris 7777 hepatoma in the rat. Korean J Med 2004;66:397-403.
28. Wiedmann M, Caca K, Berr F, et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer 2003;97:2783-2790.
29. Berr F, Wiedmann M, Tannapfel A, et al. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 2000;31:291-298.
30. Wiedmann M, Berr F, Schiefke I, et al. Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study. Gastrointest Endosc 2004;60:68-75.
31. Cheon YK, Cho YD, Baek SH, et al. Comparison of survival of advanced hilar cholangiocarcinoma after biliary drainage alone versus photodynamic therapy with external drainage. Korean J Gastroenterol 2004;44:280-287.
32. Nanashima A, Yamaguchi H, Shibasaki S, et al. Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study. J Gastroenterol 2004;39:1095-1101.
33. Utsumi K, Takai Y, Tada T, Ohzeki S, Fujiwara H, Hamaoka T. Enhanced production of IL-6 in tumor-bearing mice and determination of cells responsible for its augmented production. J Immunol 1990;145:397-403.
34. Goydos JS, Brumfield AM, Frezza E, Booth A, Lotze MT, Carty SE. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 1998;227:398-404.
35. Cheon YK, Cho YD, Moon JH, et al. Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol 2007;102:2164-2170.